Drug Abuse

Alles, G. A., ‘Some relations between chemical structure and physiological action of
mescaline and related compounds’, in Abramson, H. A. (ed.), Neuropharmacology,
Trans fourth conference, Macy Jr Foundation, USA, 1959, pp. 181–268.

Angrist, B. M., Schweitzer, J. W., Friedhoff, A. J. and Gershon, S., ‘Investigation of
p-methoxyamphetamine excretion in amphetamine induced psychosis’, Nature, 225,
1969, pp. 651–652.

Bai, F., Lau, S. S., Monks, T. J., ‘Glutathione and N-acetylcysteine conjugates of
alpha-methyl-dopamine produce serotonergic neurotoxicity: possible role in
methylenedioxyamphetamine-mediated neurotoxicity’, Chemical Research Toxicology,
12, 1999, pp. 1150–1157.

Bailey, K., A. W., Legault, D., Verner, D., ‘Identification of the N-methylated analogs
of the hallucinogenic amphetamines and some isomers’, Journal of the Association of
Analytical Chemists, 58, 1975, pp. 62–69.

Bailey, K., Verner, D. and Legault, D., ‘The identification of methoxyamphetamines,
methoxy-N-methylamphetamines and methylenedioxyamphetamine’, Microgram, 6,
1973, pp. 141–165.

Bankson, M. G. and Cunningham, K. A., ‘3,4-methylenedioxymethamphetamine
(MDMA) as a unique model of serotonin receptor function and serotonin-dopamine
interactions’, The Journal of Pharmacology and Experimental Therapeutics, 297,
2001, pp. 846–852.

Becket, A. H. and Midha, K. K., ‘The identification of four metabolic products after
incubation of p-methoxyamphetamine with liver preparations of various species’,
Xenobiotica, 4, 1974, pp. 297–312.

Bellis, M. A., Bennett, A., Chaudry, M. and Kilfoyle, M., ‘Ibiza uncovered: changes in
substance abuse among young people visiting an international nightlife resort’,
International Journal of Drug Policy, 11, 2000, pp. 235–244.

Benington, F., Morin, R. D., Clark, jr. L. C., ‘The enzymatic oxidative deamination and
effect on cat behavior of mescaline and structurally-related beta-phenethylamines’,
Alabama Journal of Medical Sciences, 4, 1964 p. 417.

Byard, R. W., Gilbert, J., James, R. and Lokan, R. J., ‘Amphetamine derivative
fatalities in South Australia — Is ‘ecstasy’ the culprit?’, American Journal of Forensic
Medicine and Pathology, 19, 1998, pp. 261–265.

Calafat, A., Fernandez, C. and Juan, M., Risk and control in the recreational drug
culture. Sonar Project, Palma de Mallorca, Irefrea, Spain, 2001.

Cession-Fossion, A., Michaux, R., ‘Cardiovascular properties of veritol and its 0-
methylated derivative in the rat’, Archives of International Pharmacodynamics and
Therapeutics, 162, 1966, pp. 226–230.

Cesura, A. M. and Pletscher, A., ‘The new generation of monoamine oxidase
inhibitors’, Progress in Drugs Research, 38, 1992, pp. 171–297.

Chance, M. R. A., ‘Aggregation as a factor influencing the toxicity of
sympathomimetic amines in mice’, Journal of Pharmacology and Experimental
Therapeutics, 87, 1946, pp. 214–219.

Chance, M. R. A., ‘Factors influencing the toxicity of sympathomimetic amines to
solitary mice’, Journal of Pharmacology and Experimental Therapeutics, 89, 1947,
pp. 289–296.

Cheng, H. C., Long, J. P., Nichols, D. E. and Barfknecht, C. F., ‘Effects of
paramethoxyamphetamine (PMA) on the cardiovascular system of the dog’, Archives
of International Pharmacology and Therapeutics 212, 1974, pp. 83–88.

Cimbura, G., ‘PMA deaths in Ontario’, Canadian Medicine Association Journal, 110,
1974, pp. 1263–1267.

Clark, C. C., ‘The identification of methoxy-N-methylamphetamines’, Journal of
Forensic Science, 29, 1984, pp. 1056–1071.

Colado, M. I., Williams, J. L. and Green, A. R., ‘The hyperthermic and neurotoxic
effects of ‘ecstasy’ (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the dark
agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype’, British Journal
of Pharmacology, 115, 1995, pp. 1281–1289.

Collison, M., ’In search of the high life: drugs, crime, masculinity and consumption’,
British Journal of Criminology, 36, 1996, pp. 428–444.

Coomber, R., ‘How the media do drugs: quality control and the reporting of drug
issues in the UK print media’, International Journal of Drug Policy, 11, 2000, pp.
217–225.

Coumbaros, J. C., Kirkbride, K. P., and Klass, G., ‘Application of solid-phase
microextraction to the profiling of an illicit drug: manufacturing impurities in illicit
4-methoxyamphetamine’, Journal of Forensic Science, 44, 1999, pp. 1237–1242.

Crespi, D., Mennini, T. and Gobbi, M., ‘Carrier-dependent and Ca2+dependent 5-HT
and dopamine release induced by (+ )amphetamine, 3,4-methylenedioxymethamphetamine,
p-chloroamphetamine and (+ )fenfluramine’, British Journal of
Pharmacology, 121, 1997, pp. 1735–1743.

Dafters, R. I., ‘Hyperthermia following MDMA administration in rats: effects of ambient
temperature, water consumption, and chronic dosing’, Physiology Behaviour, 58,
1995, pp. 877–882.

Dal Cason, T. A., ‘The identification of 4-methoxyamphetamine (PMA) and 4-
methoxymethamphetamine (PMMA)’. Microgram, 33, 2000, pp. 207–222.

Dal Cason, T. A., ‘A re-examination of the mono-methoxy positional ring isomers of
amphetamine, methamphetamine and phenyl-2-propanone’, Forensic Science
International, 119, 2001, pp. 168–194.

Daws, E. C., Irvine, R. J., Callaghan, P. D., Toop, N. P., White, J. M. and Bochner, F.,
‘Differential behavioural and neurochemical effects of para-methoxyamphetamine and
3,4-methylenedioxyamphetamine in the rat’, Progress in Neuropsychopharmacology
and Biological Psychiatry, 24, 2000, pp. 955–977.

De la Torre, R., et al., ‘Review of the pharmacological and toxicological information
on MDMA for the further development of the risk-assessment methodology’, European
Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2001.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Insights: new
trends in synthetic drugs in the European Union, Office for Official Publications of the
European Communities, Luxembourg, 1997.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Report on the
risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs,
Office for Official Publications of the European Communities, Luxembourg, 1999.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Annual
report on the state of the drugs problem in the European Union, Office for Official
Publications of the European Communities, Luxembourg, 2000.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2001a),
EMCDDA communication.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2001b),
EMCDDA communication.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2001c),
Annual report on the state of the drugs problem in the European Union, Office for
Official Publications of the European Communities, Luxembourg.

Erowid, Review of various unofficial and official information sources on PMA fatal
cases in the United States, Canada and Australia,

European Police Office (Europol), Contribution to the risk assessment (2564-141), The
Hague, Netherlands, 2001.

European Police Office (Europol), Europol communication, 2001.

Farrell, M., ‘Ecstasy and the oxygen of publicity’, British Journal of Addiction, 84,
1989, p. 943.

Felgate, H. E., Felgate, P. D., James, R. A., Sims, D. N., and Vozzo, D. C. ‘Recent
paramethoxyamphetamine deaths’, Journal of Analytical Toxicology, 22, 1998, pp.
169–172.

Golaszewski, R. F. Newsgroup, , November 2000.

Glennon, R. A., Ismaiel, A. E. M., Martin, B., Poff, D. and Sutton, M., ‘A preliminary
behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine’,
Pharmacology Biochemistry and Behavior, 31, 1988, pp. 9–13.

Glennon, R. A., Young, R., Dukat, M. and Cheng, Y., ‘Initial characterization of
PMMA as a discriminative stimulus’, Pharmacology Biochemistry and Behavior, 57,
1997, pp. 151–158.

Green, A. L. and Hait, M. A. S., ‘p-Methoxyamphetamine, a potent reversible
inhibitor of type-A monoamine oxidase in vitro and in vivo’, Journal of Pharmacy and
Pharmacology, 32, 1980, pp. 262–266.

Hegadoren, K. M., Martin-Iverson and M. T., Baker, (G. B) ‘Comparative behavioural
and neurochemical studies with a psychomotor stimulant, a hallucinogen and 3,4-
methylenedioxy analogues of amphetamine’, Psychopharmacology, 118, 1995, pp.
295–304.

Institut National de la Santé et de la Recherche Médicale, Ecstasy: des données
biologiques et cliniques aux contextes d’usage, 1997 p. 89., Inserm, Paris.

Irvine, R. J., Toop, N. P., Phillis, B. D. and Lewanowitsch, T., ‘The acute cardiovascular
effects of 3,4-methylenedioxymethamphetamine (MDMA) and p-methoxyamphetamine
(PMA)’. Addiction Biology, 6, 2001, pp. 45–54.

Kirkbride, K. P., Ward, A. D., Jenkins, N. F., Klass, G. and Coumbaros, J. C.,
‘Synthesis of 4-methyl-5-arylpyrimidines and 4-arylpyrimidines: route specific markers
for the Leuckardt preparation of amphetamine, 4-methoxyamphetamine, and 4-
methylthioamphetamine’, Forensic Science International, 115, 2001, pp. 53–67.

Kitchen, I., Tremblay, J., André, J., Dring, L. G., Idle, J. R., Smith, R. L. and Williams,
R. T., ‘Interindividual and interspecies variation in the metabolism of the hallucinogen
4-methoxyamphetamine’, Xenobiotica, 9, 1979, pp. 397–404.

Korf, D. and Lettnick, D., ‘Ecstasy: trends and patterns in the Netherlands’, in Kozel,
N. (ed.) Epidemiological trends in drug abuse. National institute on drug abuse,
Rockville, 1994, pp. 380–392.

Larner, A. J., ‘Dantrolene and ‘ecstasy’ overdose’, Anaesthesia, 48, 1993, pp.
179–80.

Lecesse, A. P., Pennings, E. J. M. and De Wolff, F. A., Combined use of alcohol and
psychotropic drugs. A review of the literature, Academisch Ziekenhuis, Leiden, 2000.

Lin, L. Y., Fujimoto, N., Di Stefano, E. W., Schmitz, D. A., Jayasinge, A. and Cho, A. K.,
‘Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine’,
Journal of Pharmacology and Experimental Therapeutics, 277, 1996, pp. 595–603.

Ling, L. H., Marchant, C., Buckley, N. A., Prior, M. and Irvine, R. J., ‘Poisoning with
the recreational drug paramethoxyamphetamine (‘death’)’, Medical Journal of
Australia, 174, 2001, pp. 453–455.

Lora-Tamayo, C., Tena, T. and Rodriguez, A., ‘Amphetamine derivative related
deaths’, Forensic Science International, 85, 1997, pp. 149–157.

Malberg, J. and Seiden, L., ‘Small changes in ambient temperature cause large
changes in MDMA induced serotonin neurotoxicty and core body temperature in the
rat’, Journal of Neuroscience, 18, 1998, pp. 5086–5094.

McElrath, K. and McEvoy, K., Ecstasy use in Northern Ireland, Queen’s University,
Belfast, 1999.

McElrath, K. and McEvoy, K., ‘Negative experiences on Ecstasy: the role of drug, set
and setting’, Journal of Psychoactive Drugs, 34 (2), 2001, pp. 199–208.

Marson, C., Schneider, S., Meys, F. and Wennig, R., ‘Structural elucidation of an uncommon
phenylethylamine analogue in urine responsible for discordant amphetamine
immunoassay results’, Journal of Analytical Toxicology, 24, 2000, pp. 17–21.

May, T., Rommelspacher, H. and Pawlik, M., ‘[3H]harman binding experiments. I: A
reversible and selective radioligand for monoamine oxidase subtype A in the CNS of
the rat’, Neurochemistry, 56, 1991, pp. 490–499.

Michaux, R., ‘Activité catatonique de certaine amines biogène et de leurs dérivés
methoxyles’, Experimental Brain Research, 3, 1967, pp. 178–183.

Michaux, R., Cession-Fossion, A., Jadot, J. and Loffet, A., ‘Action catalepsigène du
paramethoxy (2-methylaminopropyl) benzène’, Archives of International Physiology
and Biochemistry, 73, 1965, pp. 862–865.

Microgram, Vol. 34, No 9, p. 225, Drug Enforcement Administration, Washington.

Miller, R. U., Lau, S. S. and Monks, T. J., ‘Effects of intraventricular administration of
5-(glutathione-S-yl)-alpha-methyl-dopamine on brain dopamine, serotonin and
norepinephrine concentrations in male Sprague-Dawley rats’. Chemical Research
Toxicology, 9, 1996, pp. 457–465.

Miller, R. U., Lau, S. S. and Monks, T. J., ‘2,5-C glutathione-S-yl)-alpha-methyldopamine,
a putative metabolite of (alpha)-3,4-methylenedioxyamphetamine, decreases brain
serotonin concentrations’, European Journal of Pharmacology, 323, 1997, pp. 173–178.

Nabben, T., and Korf, D. J., ‘De Combiroes; Gecombineerd gebruik van alcohol met
cannabis, cocaine XTC en anfetamine’, Microgram, 34 (9), 2000, p. 225.

Ricaurte, G. A., Yuan, J. and McCann, U. D., ‘(±)3,4-
methylenedioxymethamphetamine (’Ecstasy’)-induced serotonin neurotoxicity: studies
in animals’, Neuropsychobiology, 42, 2000, pp. 5–10.

Rommelspacher, H., ‘Psychostimulanzien und Analeptika’ in Oberdisse, E., Hackenthal,
E. and Kuschinsky, K. (eds). Pharmakologie und Toxikologie. Springer Berlin,
Heidelberg, 2001, pp. 157–165.

Schweitzer, J. W., Friedhoff, A. J., Angrist, B. M., Gershon, S., ‘Excretion of
p-methoxy-amphetamine administered to humans’, Nature, 229, 1971, pp. 133–134.

Scorza, C., Silveira, R., Nichols, D. E. and Reyes-Parada, U., ‘Effects of 5-HT
releasing agents on the extracellular hippocampal 5-HT of rats’, Neuropharmacology,
38, 1999, pp. 1055–1061.

Severs, P. S., Dring, L. G. and Williams, R. T., ‘Urinary metabolites of p-hydroxyamphetamine
in man, rat, and guinea pig’, Xenobiotica, 6, 1976, pp. 345–353.

Shapiro, H., Waiting for the Man: the story of drugs and popular music, Helter Skelter,
London, UK, 1999.

Shulgin, A., ‘Psychotomimetic drugs: structure–activity relationships’, in Iversen, L. L.,
Snyder, S. H., (eds). Handbook of Psychopharmacology, 11, Stimulants, Plenum Press,
New York, US, 1978, pp. 243–333.

Shulgin, A. and Shulgin, A., ‘Pihkal. A chemical love story.’ Joy D., (ed.), Transform
Press, Berkeley, CA, US, 1991.

Shulgin, A., Sargent, T. and Naranjo, C., ‘Structure-activity relationships of one-ring
psychotomimetics’, Nature, 221, 1969, pp. 537–554.

Smythies, I. R., Johnson, U. S., Bradley, R. J., Benington, F., Morin, R. D. and Clark, L. C.,
‘Some new behavior — disrupting amphetamines and their significance’, Nature,
216, 1967, pp. 128–129.

Stafford, P., Psychedelics Encyclopaedia, Third Expanded Edition, Ronin publishing,
Berkeley, CA, USA, 1992.

Steele, T. D., Katz, J. L. and Ricaurte, G. A., ‘Evaluation of the neurotoxicity of
N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine,
PMMA)’, Brain Research, 589, 1992, pp. 349–352.

Van der Schoot, J. B., Ariens, E. J., van Rossum, J. M. and Hurkmans, J. A.,
‘Phenylisopropylamine derivatives, structure and action’, Arzneimittelforschung (drug
research), 12, 1962, pp. 902–907.

White, J. R., Obradovic, T., Imel, K. M. and Weaton, M. J., ‘The effects of
methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) on monoaminergic
neurotransmission in the central nervous system’, Progress in Neurobiology, 49,
1996, pp. 455–479.

Winstock et al., ‘The Mixmag drugs survey’, Mixmag, March, 2001, p. 42.

Wu, D., Otton, S. V., Inaba, T., Kalon, W. and Sellers, E. M., ‘Interactions of
amphetamine analog with human liver CYP2D6’, Biochemistry and Pharmacology,
53, 1997. pp. 1605–1612.

Young, R., Dukat, M., Malmusi, L. and Glennon, R. A., ‘Stimulus properties of PMMA:
effect of optical isomers and conformational restriction’, Pharmacology and
Biochemistry of Behaviour, 64, 1999, pp. 449–453.

Young, R. and Glennon, R. A., ‘Discriminative stimulus properties of amphetamine
and structurally related phenalkylamines’, Medical Research Review, 6, 1986, pp.
99–130.

< Prev		Next >